文献速递乳腺癌放疗

早期乳腺癌术前单次立体定向部分乳腺照射:病理与Ki-67评估

Preoperative Single Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer Patients With GammaPod Technology: Pathologic Findings and Ki-67 Evaluation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-02-22

这项单臂2期临床试验纳入49例绝经后、50岁以上、cT1-T2 cN0 luminal型早期乳腺癌患者,术前接受GammaPod单次30至36 Gy立体定向部分乳腺照射,8至28周后行保乳手术。主要缓解率为37%,其中病理完全缓解占18%;平均Ki-67指数从照射前9.5%降至照射后2%。作者认为术前单次立体定向部分乳腺照射似乎与有前景的主要缓解率相关,包括完全缓解病例。

要点

  • 49例早期乳腺癌术前接受GammaPod单次30至36 Gy照射,8至28周后手术。
  • 主要缓解率37%,其中病理完全缓解占18%。
  • 平均Ki-67指数由照射前9.5%降至照射后2%。

核心结论

  • 作者认为术前单次立体定向部分乳腺照射似乎与有前景的主要缓解率相关,包括完全缓解病例。

研究设计与样本

  • 单臂2期临床试验,纳入绝经后、50岁以上、早期(cT1-T2 cN0)luminal型、任何分级、单灶、适合保乳手术的乳腺癌患者。
  • 大体肿瘤体积包括肿瘤,临床靶区等同于大体肿瘤体积,计划靶区由临床靶区对称外扩3 mm形成。
  • 采用GammaPod技术行单次立体定向放射外科治疗,总剂量30至36 Gy,照射后8至28周行手术。
  • 病理反应分为病理完全缓解、残留病灶<10%的近完全缓解、残留病灶10%至90%的病理部分缓解、残留病灶>90%的稳定 disease;病理完全缓解与近完全缓解合并为「主要缓解」。
  • 2022年1月至2023年11月共49例患者入组并接受术前单次立体定向部分乳腺照射后保乳手术。

主要发现

  • 主要缓解率为37%,其中病理完全缓解占18%。
  • 平均Ki-67指数从照射前9.5%降至照射后2%。

关键数值与推荐

  • 病理反应分类:病理完全缓解、残留病灶<10%的近完全缓解、残留病灶10%至90%的病理部分缓解、残留病灶>90%的稳定疾病。
  • 主要缓解定义为病理完全缓解与近完全缓解合并。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this phase 2 clinical study is to investigate the safety and feasibility of a single fraction stereotactic partial breast irradiation (S-PBI) for early-stage breast cancer in the preoperative setting and to evaluate tumor response to a single large radiation dose through pathologic examination and immunohistochemistry analysis of the surgical specimen. METHODS AND MATERIALS: This single arm, phase 2 clinical trial includes patients in postmenopausal status, over the age of 50 years, with early-stage (cT1-T2 cN0) breast cancer, luminal type, any grade, unifocal tumor, and suitable for breast conserving surgery. The gross tumor volume includes the tumor. The clinical target volume corresponds to gross tumor volume. The planning target volume is created by adding 3 mm symmetrical margins from the clinical target volume. Treatment is delivered through GammaPod technology as single fraction radiosurgery, to a total dose of 30 to 36 Gy. Surgery is performed 8 to 28 weeks after S-PBI. Pathologic response is classified as pathologic complete response (pCR), near complete response with <10% of residual disease, pathologic partial response with 10% to 90% of residual disease, or stable disease with >90% of residual disease. We further group pCR and near complete response together as "Major Response." RESULTS: From January 2022 to November 2023, 49 patients were enrolled and underwent S-PBI followed by breast conserving surgery. The rate of Major Response was 37%, including pCR in 18% of cases. The mean Ki-67 index was reduced from 9.5% pre-S-PBI to 2% post-S-PBI. CONCLUSIONS: Preoperative single fraction S-PBI appears to be associated with a promising rate of "Major Response," including cases of complete response.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Reverberi C, Facondo G, Prisco A, et al. Preoperative Single Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer Patients With GammaPod Technology: Pathologic Findings and Ki-67 Evaluation. Int J Radiat Oncol Biol Phys. 2025. PMID: 39993536. doi:10.1016/j.ijrobp.2025.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。